Clinical Trial Update: Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update reports that the Phase 1/2 study of daily intranasal oxytocin for childhood-onset schizophrenia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood-onset Schizophrenia
• Schizophrenia

Drugs mentioned

• Oxytocin (intranasal) (oxytocin)

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Childhood Onset Psychotic Disorders, Schizophrenia | Phase 1, Phase 2 | Status: TERMINATED